Domestic pharmaceutical firms mull increasing R&D spending in 2004

Published: 2004-01-13 06:59:00

Updated: 2004-01-13 06:59:00

Amid gloomy prospects that Korea's economy would hardly pick up until mid-2004, some of major domestic pharmaceutical firms are determined to achieve their revenue targets in 2004 by giving priority to R&D sector more recruitments of talented researchers, substantial increase in R&D spending, mo...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK